Clinical Aspects on Bio-Medical Potential of Exogenous Gangliqside Application

  • B. Weisner
Conference paper
Part of the NATO ASI Series book series (volume 7)


The therapy of neurological diseases of the centralor peripheral nervous system with an intramuscularly given ganglioside mixture is a symptomatic and non-causal treatment. Diseases of ganglioside deficiency are not known. The indication for therapy with gangliosides is based on the observation that gangliosides seem to stimulate nerve cell sprouting (1, 2). Even in biological systems a faster regeneration of neurites was observed after ganglioside mixtures were given intraperitoneally or locally. These results are reported elsewhere in this symposium. They leave many questions open, especially with respect to the efficiency and the site of action of this drug.


Amyotrophic Lateral Sclerosis Diabetic Neuropathy Nerve Conduction Velocity Action Potential Amplitude Motor Nerve Conduction Velocity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Norido F, Canella R, Anorti F (1981) Accleration of nerve regeneration by gangliosides estimated by the somatosensory evoked potentials (SEP) Experimentia 37: 301Google Scholar
  2. 2.
    Gorio A, Carmignoto G, Ferari A (1981) Axon sprouting stimulated by gangliosides: A new model for elongation and spronting. Rapport A Gerio, Gangliosides in Neurological and Neuromuscular Function, Revelopment and Repair. Raven Press, New York pp. 177–195Google Scholar
  3. 3.
    Bassi S, Albizzati M, Sbacchi M, Frattola L, Massarotti M (1984) Double-Blind Evaluation of Monosialogangliosid (GM 1) Therapy in Stroke, J of Neurosci Res 12: 493–498CrossRefGoogle Scholar
  4. 4.
    Tackmann W (1986) Elektromyographie und Nervenleitgeschwindigkeit bei diabetischen, alkoholischen und medikamentös induzierten Polyneuropathien In:Neundörfer B, Sailer D. Interdisziplinäre Bestandaufnahme der Polyneuropathien. Perimed Erlangen pp. 120–122Google Scholar
  5. 5.
    Greene DA, Brown MJ, Braunstein SN, Schwartz SS, Abury AK, Winegard AJ (1981) Comparison of clinical course and segmential electrophysiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical triaets. Diabetes 30: 139PubMedCrossRefGoogle Scholar
  6. 6.
    Buchthal F, Rosenfalck A, Behse F (1984) Sensory potentials of normal and diseased nerves. In:Dyck PJ, Thomas PK, Lambert EH, Bunge R (eds.) Peripheral Neuropathy, Saunders, Philadelphia pp. 981–1015Google Scholar
  7. 7.
    Tackmann WG, Spalke G, Orginszus (1976) Quantitative histometric studies and relation of number and diameter of myelinated fibres to electrophysiological parameters in normal and sensory nerves of man. J Neurol 212: 71–84Google Scholar
  8. 8.
    Tackmann W. Kaeser HE, Berger W, Rüeger AN (1980) Sensory and motor parameters in leg nerves of diabetics: Inter-correlations and relationships to clinical symptoms. Eur Neurol 20: 344–350Google Scholar
  9. 9.
    De Blas Orlando A, Martinez Cubells J, Hernando Arrivas C, Del Pozo Garcia JM (1983) Gangliosides in the Post-surgery Treatment of Disc Protrusion. Revista Clinica Espanda 168: 193–198Google Scholar
  10. 10.
    Bernardi A, Uliari U, De Stefani D, Poluzzi P, Bernardi G, Dainese R, Caniato G (1983) I gangliosidi: nuova pro-spettiva terapeutica della neuropatia uremica. Clin Ter 104: 211–218PubMedGoogle Scholar
  11. 11.
    Mamoli B, Brunner G, Mader R, Schanda H (1980) Effects of cerebral gangliosides in the alcoholic polyneuropathies. Europ Neurol 19: 320–326PubMedCrossRefGoogle Scholar
  12. 12.
    Hallet M, Harrington H. Tyler HR, Flood T, Slater N (1984) Trials of Gangliodide Therapy for Amyotrophic lateral sclerosis and Diabetic Neuropathy in: Leeden RM, Yu RK, Rapport M, Suzuki K, Ganglioside structure, function, and biomedical potential. Plenum Press New York, London pp 575–579Google Scholar
  13. 13.
    Horowitz SH (1984) Ganglioside (Cronassial) Therapy in Diabetic Neuropathy in: Leeden RW, Yu LRU, Rapport M, Suzuki K (eds), Gangliosides structure, function, and biomedial potential. Plenum Press New York, London pp 593–600Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • B. Weisner
    • 1
  1. 1.Department of NeurologyUniversity of HamburgHamburg 20Germany

Personalised recommendations